BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BioCentury  |  Finance

Stoking the embers

Ember raises $34M from Third Rock to develop preclinical metabolic programs
Stoking the embers

Ember Therapeutics officially launched last week with a $34 million series A round from Third Rock Ventures to develop a pair of preclinical projects plucked from academia that could result in peripherally acting compounds to treat metabolic disorders, including obesity and Type II diabetes. The company is preparing to begin human testing on its own but is also in discussions with potential strategic partners.

Originally called Adipothermics Inc., Ember has used "a couple of million dollars" in seed funding over the last 12 months to license IP and...

Read the full 436 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >